Entering text into the input field will update the search result below

Eli Lilly slips while Street defends FDA setback for Alzheimer’s drug

Alzheimers Concept Horizontal

travellinglight

Eli Lilly (NYSE:LLY) continued to decline in the morning hours Friday even as several analysts defended the company after the FDA refused accelerated approval for its Alzheimer's treatment donanemab.

Cantor Fitzgerald's Louise Chen leads the pack, reaffirming the Overweight

Recommended For You

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company